Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2−/− mice by Meadows, Vik et al.
Jo
urn
al 
Pr
e-p
roo
f
Meadows et al. 1 
Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell 
migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice 
Vik Meadows1,2,3*, Lindsey Kennedy2,3*, Laura Hargrove2, Jennifer Demieville1, Fanyin Meng1,3*, 
Shohaib Virani2, Evan Reinhart2, Konstantina Kyritsi2,3*, Pietro Invernizzi4#, Zhihong Yang3, Nan 
Wu3, Suthat Liangpunsakul3, Gianfranco Alpini1,2,3* and Heather Francis1,2,3* 
1
Research, Central Texas Veterans Health Care System, 
2
Department of Medical Physiology,
Texas A&M University College of Medicine, Humanitas Clinical and Research Center, Rozzano, 
Milan, Italy4. *present address: 3Richard L. Roudebush VA Medical Center, and Division of 
Gastroenterology and Hepatology, Department of Medicine, Indiana University School of 
Medicine. #Present address: Division of Gastroenterology and Center for Autoimmune Liver 
Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. 
Address correspondence to: 
Heather Francis, Ph.D., FAASLD 
Professor of Medicine, VA Research Scientist 
Scientific Director, Indiana Center for Liver Research 
Richard L. Roudebush VA Medical Center and Indiana University, 
Gastroenterology, Medicine 
1481 W 10th street 
Indianapolis, IN 46202 
email: heafranc@iu.edu or heather.francis@va.gov  
Conflict of interest: None of the authors have any conflicts to disclose. 
This material is the result of work supported by resources at the Central Texas Veterans Health 
Care System and Richard L. Roudebush VA Medical Center. The views expressed in this article 
are those of the authors and do not necessarily represent the views of the Department of 
Veterans Affairs. The studies were supported by a SRCS Award to Dr. Alpini, VA Merit Awards 
(1I01BX003031, HF; 4I01BX000574, GA; 5I01BX001724, FM) from the United States Department 
of Veteran’s Affairs, Biomedical Laboratory Research and Development Service and NIH NIDDK 
grant (DK108959, HF) along with funds from Indiana University School of Medicine (GA and HF), 
Indianapolis, Indiana and Baylor Scott & White Institute (GA and FM), Temple, Texas. 
Journal Pre-proof
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Meadows, V., Kennedy, L., Hargrove, L., Demieville, J., Meng, F., Virani, S., … Francis, H. (2019). Downregulation of hepatic 
stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and 
liver fibrosis in Mdr2−/− mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 165557. 
https://doi.org/10.1016/j.bbadis.2019.165557
Jo
urn
al 
Pr
e-p
roo
f
Meadows et al.  
 
2 
 
 
Abstract 
Primary sclerosing cholangitis (PSC) is characterized by increased mast cell (MC) 
infiltration, biliary damage and hepatic fibrosis. Cholangiocytes secrete stem cell factor (SCF), 
which is a chemoattractant for c-kit expressed on MCs. We aimed to determine if blocking SCF 
inhibits MC migration, biliary damage and hepatic fibrosis. Methods: FVB/NJ and Mdr2-/- mice 
were treated with Mismatch or SCF Vivo-Morpholinos. We measured (i) SCF expression and 
secretion; (ii) hepatic damage; (iii) MC migration/activation and histamine signaling; (iv) 
ductular reaction and biliary senescence; and (v) hepatic fibrosis. In human PSC patients, SCF 
expression and secretion were measured. In vitro, cholangiocytes were evaluated for SCF 
expression and secretion. Biliary proliferation/senescence was measured in cholangiocytes 
pretreated with 0.1% BSA or the SCF inhibitor, ISK03. Cultured HSCs were stimulated with 
cholangiocyte supernatant and activation measured.  MC migration was determined with 
cholangiocytes pretreated with BSA or ISK03 loaded into the bottom of Boyden chambers and 
MCs into top chamber. Results: Biliary SCF expression and SCF serum levels increase in human 
PSC. Cholangiocytes, but not hepatocytes, from SCF Mismatch Mdr2-/- mice have increased SCF 
expression and secretion. Inhibition of SCF in Mdr2-/- mice reduced (i) hepatic damage; (ii) MC 
migration; (iii) histamine and SCF serum levels; and (iv) ductular reaction/biliary 
senescence/hepatic fibrosis. In vitro, cholangiocytes express and secrete SCF. Blocking biliary 
SCF decreased MC migration, biliary proliferation/senescence, and HSC activation. Conclusion: 
Cholangiocytes secrete increased levels of SCF inducing MC migration, contributing to biliary 
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damage/hepatic fibrosis. Targeting MC infiltration may be an option to ameliorate PSC 
progression. 
 
Keywords: mast cells, stem cell factor, fibrosis, PSC, migration 
 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; SMA = 
alpha smooth muscle actin; CCA = cholangiocarcinoma; CK-19 = cytokeratin 19; c-kit = KIT 
proto-oncogene receptor tyrosine kinase; EIA = enzyme immunoassay; FN-1 = fibronectin; HR = 
histamine receptor; HSC = hepatic stellate cell; hHSC = human hepatic stellate cell; IBDM = 
intrahepatic bile duct mass; Ki-67 = marker of proliferation; MC = mast cell; Mdr2-/- = multidrug 
resistance transporter 2/ABC transporter B family member 2 knock out; mMCP-1 = mouse mast 
cell protease 1; p16 = cyclin-dependent kinase inhibitor 2A; p18 = Cyclin-dependent kinase 4 
inhibitor C; PCNA = proliferating cell nuclear antigen;  PSC = primary sclerosing cholangitis;  
qPCR = quantitative PCR; SASP = senescence-associate secretory phenotype; SCF = stem cell 
factor;  SYP-9 = synaptophysin 9; WT = wild type  
 
Introduction 
 Primary sclerosing cholangitis (PSC) is characterized by increased biliary 
damage/senescence, inflammation and hepatic fibrosis. Excessive liver fibrosis and collagen 
deposition causes immense scarring of the liver and eventually, cirrhosis (1, 2). Cholangiocytes 
are the main liver cell type that is targeted during PSC and upon damage, cholangiocytes 
secrete a number of neuroendocrine factors (3, 4) and develop a senescence-associated 
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secretory phenotype (SASP) (5), which is characterized by the secretion of growth factors, 
interleukins and other mediators including stem cell factor (SCF) (6). Besides ductular reaction, 
that includes cholangiocyte proliferation and inflammation, senescent cholangiocytes also 
contribute to hepatic fibrosis by interacting with hepatic stellate cells (HSCs) (7). Currently, PSC 
is only partly managed by a few approved therapies and/or antibiotic treatments (2). These 
strategies maintain liver function and decrease the pathological side effects patients suffer 
from, including pruritis; however, new therapeutic strategies are warranted. For the past 
decade, researchers have sought to understand the potential signaling mechanisms and 
pathological indices of PSC using a genetic model, the multi-drug resistant gene 2 (Mdr2-/-) 
mice. This model presents with some of the features that mimic human PSC pathology including 
biliary damage, inflammation and hepatic fibrosis, damage that can be found as early as 4 
weeks of age and worsens as the mice age (8, 9). Previous work has demonstrated that ductular 
reaction and portal fibrosis are prominent at 12 weeks of age, thus making this time point an 
excellent tool to study the phenotypes of PSC damage (8-11).   
 Mast cells (MCs) are immune cells that secrete a number of factors upon degranulation 
and express various receptors and/or ligands on their surface. MCs are drawn to tissues and/or 
organs via strong chemoattractants that are expressed or secreted from a variety of cells (12, 
13). SCF acts as a primary chemoattractant for MCs by binding to c-Kit (i.e. SCF receptor) on 
their surface (12, 13). We have demonstrated that, during PSC (both in rodent models and 
human liver tissues), MC infiltration increases and MCs reside close by bile ducts, allowing for 
an interaction with cholangiocytes (11, 14). Additionally, it has been shown that cholangiocytes 
secrete increased amounts of SCF during damage such as cholangiocarcinoma (CCA) and during 
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liver regeneration (15, 16). Furthermore, there is an increase in c-Kit expression in the livers 
from Mdr2-/- mice (PSC model) and in human PSC (11, 17). Taken together, these findings 
suggest that there may be a signaling relationship between cholangiocytes and MCs via SCF/c-
Kit. 
After migration to the liver, MCs contribute to hepatic fibrosis by promoting HSC 
activation and also play a role in enhancing inflammation (11, 14, 17). Multiple studies from our 
group have demonstrated how inhibition of MC mediators (i.e. histamine or histamine 
receptors) decreases PSC damage and improves cholangiocyte function. Treatment with 
cromolyn sodium (MC stabilizer) (17, 18) or either the H1 or H2 histamine receptor (HR) 
antagonists (11) decreases biliary damage, inflammation, and hepatic fibrosis in Mdr2-/- mice. In 
CCA studies, these compounds blocked tumor growth and angiogenesis and, in vitro, we found 
that inhibition of SCF decreases MC migration, CCA proliferation and angiogenesis (15). These 
studies set up the rationale for our current study to evaluate the role of the SCF/c-Kit 
interaction during PSC.  
Since our studies have revealed that (i) MC infiltration increases during PSC and (ii) 
biliary senescence promotes hepatic fibrosis, we aimed to determine if inhibition of biliary SCF 
decreases MC migration with subsequent decreased biliary damage, inflammation, and hepatic 
fibrosis.  
Methods and Materials 
Reagents and other materials 
 Chemical grade reagents were purchased from Sigma-Aldrich Co (St. Louis, MO) unless 
stated otherwise. Table 1 contains a list of all antibodies and primers used in the study. Total 
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RNA was isolated by the TRI Reagent from Sigma Life Science and reverse transcribed with the 
Reaction Ready First Strand cDNA Synthesis kit (Qiagen, Valencia, CA) (11, 19). For staining in 
liver sections, samples were sectioned 4-6 m and 10 fields were analyzed from 3 samples from 
at least 4 animals per group. For staining in human sections, samples were sectioned at 4-6 m 
and 10 fields were analyzed from 3 samples per group.   
 In vitro, we used a number of cell lines including murine mouse cholangiocytes 
(immortalized cell line generated in our lab and used by us previously (11, 14)), mouse liver-
derived MCs (MC/9, ATCC® CRL-8306™), and human hepatic stellate cells (hHSCs, ScienCell, 
Carlsbad, CA). All cell lines were maintained according to our published protocols (11). Detailed 
experiments are described below.  
In vivo models 
 For our animal studies we used the Mdr2-/- mouse model of PSC, which are raised on 
FVB/NJ background (wild-type, WT) (8, 17).  Male WT and Mdr2-/- mice were treated with either 
Mismatch Morpholino (CTTGTTGATAACGAAAGCCACCGCT) or SCF Vivo-Morpholino 
(CTTCTTCATAAGGAAAGGCAGCGCT) given by tail vein injection 2x/week for 1 week (4 g/100 l 
NaCl) as described (20, 21). Male mice (4 mice per group) were euthanized at 12 weeks of age, 
which display an increase in PSC-induced hepatic damage (10, 17).  All mice were kept in 
standard conditions including 12/12 light dark cycle and standard chow and water. From these 
groups of mice, we collected liver blocks (frozen and paraffin-embedded), serum, isolated 
cholangiocytes and hepatocytes, as described (17, 19). Cholangiocyte (1 million cells/100 l) 
and hepatocyte (1 million cells/100 l) supernatants were collected after incubation at 37 for 
4-6 hours.  
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SCF Expression and Secretion 
 In WT and Mdr2-/- mice treated with either Mismatch or Vivo-Morpholino, we measured 
SCF expression (co-stained with either CK-18 to mark hepatocytes or CK-19 to identify SCF-
positive cholangiocytes) by immunofluorescence as previously described by us using frozen liver 
sections (4-6 um) (17). SCF secretion was measured in serum and isolated cholangiocyte or 
hepatocyte supernatants by EIA (16). By western blotting, we measured SCF expression in both 
total liver and isolated hepatocytes, as well as hepatocyte gene expression by qPCR. 
To determine SCF expression patients with PSC, human liver sections from normal 
controls (collected as part of liver CCA resection and considered non-diseased areas) and PSC 
patients were used (Table 2). PSC patients presented with late PSC phenotypes, as described in 
our previous work (17). Liver sections were obtained by needle biopsies from three control 
patients and three late stage PSC (with or without cirrhosis) along with the collection of serum. 
The de-identified samples were provided by Dr. Pietro Invernizzi under a protocol approved by 
Humanitas Research Hospital; the protocol was approved by the Central Texas Veteran’s Health 
Care System Institutional Review Board and Research Development Committee. SCF/CK-19 
immunofluorescence (with 3D zoom) was performed to identify SCF-positive cholangiocytes in 
human control and PSC samples and EIA was used to determine SCF serum secretion.  
Hepatic Damage  
 Hepatic damage including necrosis and inflammation was determined in paraffin-
embedded liver sections (4-5 m thick) by Hematoxylin & Eosin Y (H&E) staining in all groups of 
mice. Aspartate aminotransferase (AST) and alanine transaminase (ALT) were determined by 
IDEXX Catalyst One test slides (IDEXX, Westbrook, ME) in serum from all groups of mice (5, 7).  
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Mast Cell Infiltration/Activation and Histamine Signaling 
 The presence of MCs was detected by immunohistochemistry for mouse MC protease-1 
(mMCP-1) in paraffin-embedded liver sections (4-5 m thick) from WT and Mdr2-/- mice treated 
with Mismatch or SCF Vivo-Morpholino (11, 19). Histamine secretion was measured by EIA (11, 
17) in serum from all groups of mice and the mRNA expression of histamine receptors (HRs) 1-4 
and MC markers: chymase, tryptase, and c-kit (17) were determined in total liver by qPCR.  
Intrahepatic Bile Duct Mass (IBDM), Biliary Proliferation, Hepatic Fibrosis, and Cholangiocyte 
Senescence 
 In all groups of mice, we measured the following: IBDM was determined by 
immunohistochemistry in paraffin-embedded liver sections (4-6 m) for CK-19, whereas biliary 
proliferation was measured by Ki-67 immunohistochemistry in paraffin-embedded liver 
sections. Both IBDM and biliary proliferation were semi-quantified using a light microscope and 
Image-Pro Analyzer, DC Imaging, West Chester, OH (5, 11, 20).  
 To determine the effects of SCF inhibition on hepatic fibrosis, we performed Sirius 
Red/Fast Green staining in liver sections (with semi-quantification) and qPCR for -smooth 
muscle actin (-SMA) in total liver (11, 14, 17). HSC presence was determined by 
immunofluorescence for desmin in all groups of mice in frozen liver sections.  
 Since SCF is also considered to be a cellular senescence-associated secretory phenotype 
(SASP) (6), we determined if biliary senescence was changed in cholangiocytes. Mice were 
evaluated for senescent factors including p18 by qPCR and p16 by immunofluorescence in 
frozen liver sections (4-6 m thick) co-stained with CK-19 to image bile ducts (7, 21).  
In Vitro Studies 
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 First, immortalized murine cholangiocyte lines (11, 22) were evaluated for SCF 
expression and cultured MCs (14, 17) evaluated for c-Kit expression by immunofluorescence. To 
validate our in vivo findings, we next determined the effects of SCF inhibition on biliary 
proliferation by treating cultured cholangiocytes with the SCF inhibitor, ISCK03 (10 M, 24 hrs 
(abcam, Cambridge, MA) dissolved in 0.1% DMSO (15)) before evaluating PCNA mRNA 
expression by qPCR. In addition, biliary senescence was measured in cholangiocytes treated 
with control or the SCF inhibitor by measuring the expression of p16 and p18 by qPCR.  
Using cultured human HSCs (hHSCs) (11), we determined if there was a direct effect on 
HSC activation via biliary SCF. Supernatants from immortalized murine cholangiocyte lines were 
collected by centrifugation after treatment with the SCF inhibitor (or vehicle control) and 
cocultured with hHSCs for 48 hrs, before measuring Synaptophysin-9 (SYP-9) and fibronectin 
(FN-1) by qPCR (11, 17).  
Finally, since cholangiocytes secrete SCF and we hypothesize that increased SCF induces 
MC migration, we performed in vitro studies to block this interaction. Murine cholangiocyte 
lines were placed in the bottom of a Boyden Chamber and subsequently treated with the SCF 
inhibitor, ISCK03 (10 M) for 24 hrs to inhibit biliary SCF/c-kit signaling (15). After 24 hrs, MCs 
were then placed in the upper chamber and migration through the membrane (Corning® 
BioCoat™ Matrigel® Invasion Chamber with PET 8 m membrane) was evaluated after 24 hrs. 
Following methanol fixation, MC presence in the transwell membrane was determined by 
Toluidine Blue staining and semi-quantified using a light microscope (15).  
Statistical Analysis 
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All data is expressed as mean ± SEM. Groups were analyzed by the Student unpaired t 
test when two groups are analyzed or a two-way ANOVA when more than two groups are 
analyzed, followed by an appropriate post hoc test. p<0.05 was considered significant.  
  
Results 
SCF biliary expression and secretion increases in human PSC and Mdr2-/- mice treated with 
Mismatch Morpholino 
 By immunofluorescence, we demonstrated that SCF expression (primarily in 
cholangiocytes identified by CK-19 staining) increased in patients with late-stage PSC compared 
to control tissues collected from non-diseased areas (Figure 1A). Further, patients with PSC 
have an increased amount of circulating SCF compared to controls (Figure 1B). In WT mouse 
groups, there were no changes in SCF expression (Supplemental Figure 1); however, Mdr2-/- 
mice treated with mismatch Morpholino have increased SCF expression (primarily in 
cholangiocytes) shown by immunofluorescence (Figure 1C), which was absent in mice treated 
with SCF Vivo-Morpholino (Figure 1C). In serum from WT Mismatch and SCF Vivo-Morpholino, 
SCF levels were unchanged; however, Mdr2-/- Mismatch mice had increased amounts of SCF 
that was reduced in Mdr2-/- SCF Vivo-Morpholino mice (Figure 1D). Finally, biliary secretion of 
SCF was increased in Mdr2-/- mice treated with Mismatch compared to WT (no changes were 
noted between WT groups) which was decreased in cholangiocyte supernatants from Mdr2-/- 
mice treated with SCF Vivo-Morpholino (Figure 1E).  
Hepatocyte SCF expression and secretion are unchanged in Mdr2-/- mice treated with 
Mismatch or SCF Vivo-Morpholino  
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We found that SCF expression did not markedly change in total liver or isolated 
hepatocytes between all groups as shown by western blotting (Supplemental Figure 2A) and 
immunofluorescence (WT groups not shown), Supplemental Figure 2B). In addition, hepatocyte 
SCF mRNA and protein expression did not significantly increase in Mdr2-/- SCF Mismatch mice 
when compared to WT SCF Mismatch (Supplemental Figure 2A-C). Finally, hepatocyte SCF 
secretion was not increased in Mdr2-/- SCF Mismatch mice compared to WT SCF Mismatch; 
there was no difference between Mdr2-/- treated with SCF Mismatch or Vivo-Morpholino 
(Supplemental Figure 2D). This data supports our theory that biliary SCF (but not hepatocyte 
SCF) is critical to MC migration and subsequent damage during PSC progression.  
Hepatic damage decreases in Mdr2-/- mice treated with SCF Vivo-Morpholino  
By H&E, we found that inhibition of SCF decreased hepatic necrosis and portal 
inflammation in Mdr2-/- mice treated with Mismatch (Supplemental Figure 3A); there were no 
changes between WT Mismatch and SCF Vivo-Morpholino treatments. H&E in human PSC 
shows ductular reaction, necrosis and inflammation when compared to human controls 
(Supplemental Figure 3B) The levels of AST and ALT increased in Mdr2-/- mice treated with 
Mismatch compared to WT mice, which were reduced when Mdr2-/- mice were treated with 
SCF Vivo-Morpholino (Supplemental Figure 3C).  
Inhibition of SCF decreased MC migration/activation and histamine signaling 
 Serum histamine levels were decreased in WT mice treated with SCF Vivo-Morpholino 
compared to Mismatch and, in Mdr2-/- mice treated with Mismatch, histamine levels were 
significantly increased compared to both WT groups, which was reduced in Mdr2-/- mice treated 
with SCF Vivo-Morpholino (Figure 2A). By immunohistochemistry for mMCP-1 there were no 
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MCs found in WT mice treated with Mismatch or SCF Vivo-Morpholino, which is consistent with 
our previous work showing that WT mice typically display few to no MCs around the portal area 
(11). In Mismatch Mdr2-/- mice, MC presence was increased in the portal area (inset: red arrows 
= MCs; black arrow = bile duct); which was reduced in Mdr2-/- mice treated with SCF Vivo-
Morpholinos (Figure 2B). Further, the mRNA expression of MC markers increased in Mdr2-/- 
Mismatch mice compared to WT (no difference between Mismatch and SCF Vivo-Morpholino 
treatment) and were reduced in SCF Vivo-Morpholino Mdr2-/- mice (Supplemental Figure 4A). 
Finally, the expression levels of H1-H4 HRs were increased in Mdr2-/- mice treated with 
Mismatch compared to WT (no difference between Mismatch and SCF Vivo-Morpholino); 
however, blocking SCF in Mdr2-/- mice resulted in the reduction of H1, H2 and H4 HR, whereas 
H3 HR was not changed (Supplemental Figure 4B).  
IBDM, biliary proliferation, hepatic fibrosis, and senescence decreased after inhibition of SCF 
in Mdr2-/- mice 
 In WT Mismatch and SCF Vivo-Morpholino treated mice there was no difference in 
IBDM, biliary proliferation, hepatic fibrosis, and cholangiocyte senescence (Figures 3, 4, 5). 
Mdr2-/- mice treated with Mismatch displayed an increase in (i) IBDM and biliary proliferation as 
shown by CK-19 and Ki-67, respectively (Figure 3A and 3B); (ii) collagen deposition, primarily 
around the portal area (Figure 4A) and supported by semi-quantification (Figure 4B); (iii) HSC 
presence shown by immunofluorescence for desmin (Figure 4C) along with the mRNA 
expression of -SMA (Figure 4D); and (iv) biliary p18 and p16 expression (Figure 5A-5B). All of 
these parameters decreased in Mdr2-/- mice treated with SCF Vivo-Morpholino demonstrating 
that manipulation of SCF regulates liver damage (Figures 3-5).  
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Inhibition of biliary SCF decreased (i) cholangiocyte proliferation/senescence, (ii) hHSC 
activation; and (iii) MC migration, in vitro 
 In vitro, by immunofluorescence, we found that (i) cholangiocytes express SCF and (ii) 
MCs express c-Kit (Figure 6A). By qPCR, the expression of PCNA (Figure 6B) and the senescent 
markers, p16 and p18 (Figure 6C) all decreased after cholangiocytes were treated with the SCF 
inhibitor (ISCK03). These results support our in vivo studies that demonstrate that inhibition of 
SCF decreases biliary damage and senescence. Similarly, we measured HSC activation in vitro 
after stimulation with cholangiocyte supernatants (control and pre-treatment with the SCF 
inhibitor) and found that inhibition of biliary SCF decreases hHSC activation by reducing the 
expression of SYP-9 and FN-1 shown by qPCR (Supplemental Figure 5). In vitro, blocking 
cholangiocyte SCF signaling decreased (i) secretion of biliary SCF (Figure 7A) and (ii) MC 
migration toward cholangiocytes assayed by Boyden Chamber migration (Figure 7B) and 
quantified using Toluidine Blue staining (Figure 7C).  
 
Discussion 
 Our current study demonstrates that increased biliary SCF may induce MC migration to 
the liver following damage. We show that patients with PSC have increased biliary SCF 
expression and serum levels that are also reflected in Mdr2-/- mice treated with Mismatch 
Morpholinos. Biliary, but not hepatocyte, SCF secretion increases in Mdr2-/- Mismatch mice 
suggesting that our findings are cholangiocyte-specific. Inhibition of SCF using Vivo-Morpholino 
treatment decreased (i) biliary damage/senescence, (ii) MC migration and histamine signaling 
and (iii) hepatic fibrosis. Our in vitro studies demonstrated that inhibition of biliary SCF inhibited 
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MC migration. Taken together our study highlights the potential therapeutic effects of blocking 
MC migration and activation via inhibition of SCF.  
 SCF has been touted as one of the most critical regulators of MC migration, 
degranulation and activation as well as being responsible for MC phenotype after migration, 
and the SCF/c-Kit interaction has been studied extensively in tumorigenesis, wound healing and 
allergic responses (23). The SCF/c-Kit interaction has been shown to contribute to the 
development and progression of intrahepatic CCA (24). It has been shown that CCA tumors 
have 20-fold higher expression of SCF than normal tissue, which supports our findings that SCF 
expression and secretion increase in human PSC. Since PSC patients are at greater risk for CCA 
(1) and SCF is enhanced in both PSC and CCA (15), it might be feasible that SCF is a regulator of 
the transition between PSC and CCA.  Aside from being a growth factor, SCF is a well-known 
chemoattractant, and studies using a mutant MC line that lacks c-Kit demonstrate that MC 
migration is inhibited, but migration was not altered by interleukin (IL)-3 stimulation (25) 
suggesting that the SCF/c-Kit relationship may be tightly regulated.  
Besides SCF/c-Kit, there are studies demonstrating various chemoattractants which 
induce MC migration and activation. In rat peritoneal MCs, tumor necrosis factor (TNF, a potent 
MC chemoattractant (12)) induced MC migration, that was blocked when either TNF or TNF-
receptor 1 antibodies were used (26), and the interleukin (IL)-33 has also been described as a 
potent chemoattractant as well as inducing MC degranulation. The classic FCR1/IgE interaction 
is a regulator of MC migration and degranulation especially during allergic responses and 
asthmatic episodes (27). Similar to our findings demonstrating decreased hepatic damage after 
blocking SCF, inhibition of SCF/c-Kit also reduced pulmonary hypertension and vascular 
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remodeling in a model of chronic hypoxia (28). Further, in a model of pancreatic cancer, 
inhibition of SCF/c-Kit blocked invasion and metastasis via PI3K/AKT and ERK signaling (29).  
PSC is characterized by hepatic fibrosis and our current study supports our previous 
work demonstrating that blocking MC infiltration and degranulation decreases liver fibrosis and 
HSC activation (11, 14, 15, 17, 18). To support this, it has been shown that the SCF/c-Kit 
interaction promotes renal interstitial fibrosis (30). Similar to our current findings, the authors 
found that, in a diabetic kidney disease model, the expression of fibronectin and collagen type-
1a increases in diseased rats compared to normal and this was associated with increased SCF 
and c-Kit gene expression (30). Additionally, following 70% partial hepatectomy, SCF levels 
increase over time and peak at 7 days (16). This study demonstrated that SCF contributes to 
biliary remodeling and liver regeneration via increased chemokine and cytokine signaling, which 
supports our current study that SCF may alter biliary senescence and contribute to damage and 
hepatic fibrosis.  
Biliary senescence is a feature that has been found to regulate PSC and may contribute 
to an increase in damage and hepatic fibrosis (5, 7). When cholangiocytes become senescent 
they develop a SASP that is characterized by an increase in the release of inflammatory 
mediators including TGF-1 and SCF. Since MCs are found in close proximity to bile ducts, we 
hypothesize that senescent cholangiocytes may drive MC infiltration following liver injury. In 
support of this, most of the chemoattractants that promote MC migration are considered SASP 
factors that are secreted by cholangiocytes upon damage and include: SCF; growth factors like 
vascular endothelial growth factor and nerve growth factor; and interleukins such as IL-6 and IL-
8 (6). Our work herein demonstrates that inhibition of SCF/c-Kit signaling decreases biliary 
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senescence with a subsequent decrease in MC activation and hepatic damage. Interestingly, we 
did not find any alterations in TGF-1 expression after inhibition of SCF (data not shown). The 
neuroendocrine phenotype that is displayed in cholangiocytes during ductular reaction (4) 
potentially supports MC migration and subsequent degranulation, which contributes to 
enhanced disease progression.  
Targeted therapies for PSC are significantly lacking, and the current study and previous 
work from our lab present the novel concept of potential targeted therapy via manipulation of 
MCs and their mediators. In MC-deficient mice subjected to bile duct ligation, we found a 
decrease in biliary damage, inflammation and hepatic fibrosis, but when MC-deficient mice 
(typically normal livers void of damage) were subjected to tail vein injections of cultured MCs, 
biliary injury and collagen deposition significantly increased (14). While more studies are 
warranted to understand MC migration in vivo; our study presents the novel concept that 
blocking biliary senescence/SASP decreases MC presence and subsequent liver damage. This 
study also demonstrates the critical role that MCs play during liver injury and their significant 
contribution to disease progression. Since MCs are not critical to the overall function of the 
liver, targeting their mediat rs or activation may be an alternative strategy to battling PSC and 
other liver diseases.  
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Figure 1: SCF expression and secretion in PSC patients and in Mdr2-/- mice. SCF expression 
shown by immunofluorescence (CK-19 (green) and SCF (red)) (A) and serum secretion (B) 
increase in patients with PSC compared to controls. In Mdr2-/- mice treated with Mismatch 
there is increased SCF expression (co-localized with CK-19 (red) to mark SCF-positive bile ducts) 
(C) and serum secretion (D) that are reduced when mice are treated with the SCF Vivo-
Morpholino (C-D). There were no changes in SCF serum secretion between WT Mismatch and 
WT SCF Vivo-Morpholino (D). Cholangiocyte SCF secretion increased in supernatants from 
Mdr2-/- Mismatch mice compared to WT groups; however, SCF secretion was blocked in 
cholangiocyte supernatants from Mdr2-/- mice treated with SCF Vivo-Morpholino (E). Data are 
mean  SEM of 9-12 experiments for qPCR and 15 experiments for EIA. *p<0.05 vs. WT SCF 
Mismatch; #p<0.05 vs. Mdr2-/- SCF Mismatch mice. Representative images x80.  
 
Figure 2: MC migration/activation and histamine signaling in WT and Mdr2-/- mice treated 
with SCF Mismatch or SCF Vivo-Morpholinos. Serum histamine levels were decreased in WT 
mice treated with SCF Vivo-Morpholino compared to Mismatch. In Mdr2-/- Mismatch mice, 
serum histamine increased, but was reduced back to WT levels in Mdr2-/- mice treated with SCF 
Vivo-Morpholino (A). By immunohistochemistry for m-MCP1 no MCs were detected in either 
WT group; however, there was an infiltration of MCs in Mdr2-/- mice treated with Mismatch 
(red arrows (MCs) and black arrow (bile duct) shown in insert). Mdr2-/- mice treated with SCF 
Vivo-Morpholino did not display any MC migration/infiltration (B). Data are mean  SEM of 12 
experiments for EIA. *p<0.05 vs. WT SCF Mismatch; #p<0.05 vs. Mdr2-/- SCF Mismatch mice. 
Representative images x20 (inset images = 100x). 
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Figure 3: IBDM and biliary proliferation in WT and Mdr2-/- mice treated with SCF Mismatch or 
SCF Vivo-Morpholinos. By immunohistochemistry and semi-quantification for CK-19 (A) and Ki-
67 (B) we found that IBDM and biliary proliferation were unchanged in WT groups; however, 
there was a significant increase in Mdr2-/- Mismatch treated mice. Further, inhibition of SCF in 
Mdr2-/- mice reduced both IBDM (A) and biliary proliferation (B) compared to Mdr2-/- Mismatch 
mice. Data are mean  SEM of 10 experiments from 4 mice per group. *p<0.05 vs. WT SCF 
Mismatch; #p<0.05 vs. Mdr2-/- SCF Mismatch mice. Representative images x20.  
 
Figure 4: Hepatic fibrosis and HSC activation in WT and Mdr2-/- mice treated with SCF 
Mismatch or SCF Vivo-Morpholinos. Collagen deposition shown by Sirius Red/Fast Green 
staining (A) and semi-quantification (B) was unchanged in WT groups, but significantly 
increased in Mdr2-/- mice treated with Mismatch. When Mdr2-/- mice were treated with SCF 
Vivo-Morpholino, collagen deposition was reduced compared to Mdr2-/- Mismatch mice (A-B). 
The expression of desmin (C) and the gene expression of -SMA (D) did not change in WT 
groups; however, there was a significant increase in both found in Mdr2-/- Mismatch mice that 
was reduced in the Mdr2-/- mice treated with SCF Vivo-Morpholino (C-D). Data are mean  SEM 
of 10 experiments from 4 mice per group for Sirius Red/Fast Green staining and 12 experiments 
for qPCR. *p<0.05 vs. WT SCF Mismatch; #p<0.05 vs. Mdr2-/- SCF Mismatch mice. 
Representative images x40.  
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Figure 5: Biliary senescence in WT and Mdr2-/- mice treated with SCF Mismatch or SCF Vivo-
Morpholinos. By real-time PCR (A) we found no change between WT groups in the expression 
of p18; however, there was an increase in p18 expression in Mdr2-/- Mismatch mice which was 
reduced when Mdr2-/- mice were treated with SCF Vivo-Morpholinos (A). By 
immunofluorescence (B) we found an increased expression of p16 in cholangiocytes (marked by 
white arrows to show co-localization) in Mdr2-/- Mismatch mice compared to controls that was 
decreased in Mdr2-/- mice treated with SCF Vivo-Morpholino (B). Data are mean  SEM of 9 
experiments for qPCR. *p<0.05 vs. WT SCF Mismatch; #p<0.05 vs. Mdr2-/- SCF Mismatch mice. 
Representative images x20.  
 
Figure 6: In vitro evaluation of biliary SCF signaling. By immunofluorescence we found that 
cultured MCs express c-Kit and cultured cholangiocytes express SCF (A). Inhibition of SCF using 
ISCK03 (10 M, 24 hrs) blocked the gene expression of cholangiocyte PCNA (B) and p16 and p18 
(C). Data are mean  SEM of 12-15 experiments for qPCR. *p<0.05 vs. cholangiocyte control. 
Representative images x20.  
 
Figure 7: In vitro cholangiocyte SCF secretion and MC migration. By EIA we found that 
cholangiocyte SCF secretion decreases after inhibition using ISCK03 (10 M, 24 hrs) (A). Boyden 
chambers were loaded with cholangiocytes treated either with 0.1% BSA (control) or ISCK03 (10 
M, 24 hrs) into the bottom chamber and cultured MCs were placed in the upper chamber and 
MC migration was measured after 24 hrs (B). MC migration was significantly blunted when 
cholangiocytes were treated with the SCF inhibitor, ISCK03 compared to control as shown by 
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Toluidine Blue staining (C). Data are mean  SEM of 9-12 experiments for EIA and 3 
experiments for migration. *p<0.05 vs. cholangiocyte control. Representative images x20.  
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Table 1 
 
Antibodies          
(use, dilution) 
Source Catalog no. 
a-SMA (IF, 1:100) Abcam, Cambridge, UK ab5694 
CK19 (IF, 1:100) 
Developmental Studies Hybridoma 
Bank, Univ. of Iowa, Iowa City, IA) 
TROMA-III (Krt19 
Antibody) 
CK19 (IHC, 1:200) Abcam, Cambridge, UK ab52625 
Desmin (IF, 1:100) Abcam, Cambridge, UK ab15200 
Ki67 (IHC, 1:100) Abcam, Cambridge, UK ab15580 
p16 (IF, 1:100 ) Abcam, Cambridge, UK ab189034 
p18 (IF, 1:100) Abcam, Cambridge, UK ab192239 
p21 (IF, 1:100) Abcam, Cambridge, UK ab188224 
SCF (IF, 1:100) Abcam, Cambridge, UK ab64677 
SYP-9 (1:250) Abcam, Cambridge, UK ab52636 
 
 
Primers 
(gene name) 
Source Catalog no. 
-SMA (Acta2) Qiagen, Valencia, CA PPM04483A 
CK19 (Krt19) Qiagen, Valencia, CA PPM02968A 
Fibronectin (Fn1) Qiagen, Valencia, CA PPM03786A 
p16 (Cdkn2a) Qiagen, Valencia, CA PPM02906F 
p18 (Cdkn2c) Qiagen, Valencia, CA PPM02893C 
p21 (Cdkn1a) Qiagen, Valencia, CA PPM02901B 
PCNA (Pcna) Qiagen, Valencia, CA PPM03456A 
SCF (Kitl) Qiagen, Valencia, CA PPM02983C 
SYP-9 (Syp) Qiagen, Valencia, CA PPM03241A 
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Table 2  Characteristics of liver donors of normal controls and PSC  
 
 Year of 
Birth 
Sex Pathological 
Diagnosis 
Cirrhosis 
Normal Control 1 58 Female Normal No 
Normal Control 2 58 Female Normal No 
Normal Control 3 62 Female Normal No 
PSC 1 56 Female Advanced stage No 
PSC 2 50 Female Early - advanced stage No 
PSC 3 37 Female Early - advanced stage No 
PSC = primary sclerosing cholangitis 
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Highlights:  
 
 Mast cells migrate to the liver during damage and contribute to liver fibrosis during 
primary sclerosing cholangitis (PSC) 
 Migration of mast cells is regulated by paracrine signals from damaged cholangiocytes 
 Damaged cholangiocytes express and secrete stem cell factor (SCF) and SCF is 
upregulated in human PSC  
 Inhibition of SCF blocks mast cell migration and ameliorates liver damage and hepatic 
fibrosis 
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